SecBot SecBot
8-K ·Filed Apr 13, 2026

SYRE

Spyre Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed7mo ago SEC0001628280-26-024906
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The termination of the ATM program is a signal of financial discipline or reduced near-term capital needs, but investors should watch for final Q1 2026 financials and pipeline updates as the next catalyst. The strong cash position supports operations into 2028 as previously guided.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$64.01
T+0 close · Apr 13, 2026 · via day close
Latest settled
+54.27%
T+60 · $98.75
Vs SPY
+45.75%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 14 $64.01entry
  2. T+1 · 7mo ago +7.78%α +7.01% · $68.99
  3. T+5 · 7mo ago +11.34%α +9.95% · $71.27
  4. T+20 · 6mo ago +19.40%α +13.11% · $76.43
  5. T+60 · 4mo ago +54.27%α +45.75% · $98.75
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Spyre Therapeutics reported preliminary cash of $741M as of March 31, 2026, including $30M from legacy asset sales, while terminating its ATM offering. The cash update is positive, but halting equity financing suggests caution despite strong liquidity.

Key Financial Metrics

EPS
−$0.70
est −$0.66 · -6.1%
Revenue
$0.00
est $0.00 · 0.0%
Rating
in line

Key Facts

  • Company expects ~$741M in cash, cash equivalents, and marketable securities as of March 31, 2026
  • Cash includes $30M from legacy asset disposition, $23M of which is expected to be paid to CVR holders in Q2 2026
  • Terminated at-the-market (ATM) prospectus, halting common stock sales under the existing agreement
  • Sales Agreement with TD Securities remains in effect; new prospectus would be needed to restart sales
  • No financial results finalized; this filing provides only preliminary cash guidance

Financial Impact

$741M cash position as of March 31, 2026, up from $486.2M reported on September 30, 2025

cashliquiditydilution

Risk Factors

  • Preliminary figures are subject to change upon audit and final closing procedures
  • Termination of ATM may signal reduced confidence in near-term equity markets or strategic shift in capital raising

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-024906
Document: 0001628280-26-024906-index-headers.html0001628280-26-024906
Document: 0001628280-26-024906-index.html0001628280-26-024906
Document: 0001628280-26-024906.txt0001628280-26-024906
8-K Data (Synthetic)0001628280-26-024906

Track record

36 reports on SYRE

Performance horizon

8 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +54.27% at T+60 after the Apr 13, 2026 report. 15 of 21 went positive at some point.

Filters
  1. Nov 3, 202613d ago 8-K Neutral 5/10 No price data
  2. Nov 3, 202613d ago Press Release Bearish 5/10 Entry $99.04 Now $99.37 −0.33% settles Feb 2
  3. Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
  4. Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
  5. Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
  6. Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
  7. Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  8. Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  9. Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  10. Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
Showing 10 of 36

US Market Status

Market Closed · Opens in 8h 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 13, 2026